Proposition 38 on California's November 3, 2026 ballot authorizes $8.4 billion in general obligation bonds for immunology and immunotherapy research, with half directed to a University of California-affiliated institute and half to competitive grants at public and nonprofit institutions. At least $4.2 billion must target cancer, heart disease, and Alzheimer’s research, alongside requirements for 20% price discounts on resulting treatments in California and 10% revenue sharing with the state General Fund. Trader consensus around 55.5% for passage reflects Democratic Party and health organization endorsements alongside fiscal concerns over $500–600 million in annual General Fund repayments for roughly 20 years. Recent voter guides highlight the measure’s qualification via petition signatures in June 2026 and note potential offsets from research revenue, amid reduced federal medical research funding. Historical precedent from prior stem cell bond measures informs assessments of passage odds in this closely divided contest.